Gut help to prevent diarrhea from EGFR-targeted lung cancer drugs
Part of Cancer, Lungs & breathing clinical trials.
This Phase 3 trial tests whether adding glutamine plus L. reuteri can help prevent severe diarrhea caused by EGFR-targeted treatments in people with advanced non-small cell lung cancer. If it works, it could make treatment easier to tolerate and help you stay on the planned therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and able to consent
- Have non-small cell lung cancer confirmed by biopsy/pathology
- Have stage IIIB, IIIC, or IV (advanced disease)
- Be starting an EGFR-targeted pill treatment (1st or 2nd generation), like an EGFR TKI
- Be well enough for study participation (ECOG 0–2) and expected to live more than 8 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether adding metformin to standard targeted medicines (tyrosine kinase inhibitors) helps people with EGFR-mutated non-small cell lung cancer. It’s meant for people who haven’t already had EGFR-targeted treatment and who have healthy enough labs and organs to safely take the study medicines.
This study tests whether a probiotic supplement (LR607) can help patients with newly diagnosed non-small cell lung cancer—a common type of lung cancer. Probiotics are beneficial bacteria that may help your immune system fight cancer alongside standard treatments.
This trial tests whether taking probiotics can help prevent diarrhea caused by the breast cancer drug neratinib. If you are a woman with HER2-positive breast cancer and are about to start neratinib, this study may help manage a common side effect.
This Phase 2 trial studies whether an EGFR-targeted pill, given after surgery, can reduce the chance of lung cancer coming back. It specifically looks at people whose tumors have certain EGFR changes and where “minimal residual disease” (tiny leftover cancer) is being used to guide treatment.
This study tests whether giving a combination of chemotherapy and immunotherapy before surgery can improve outcomes for people with non-small cell lung cancer. Researchers are also studying how the bacteria in your gut (microbiome) affect how well the treatment works. This approach may shrink the tumor and make it easier to remove surgically.
This study tests whether a special diet low in leucine (an amino acid) combined with chemotherapy and immunotherapy can safely treat advanced stomach cancer that has spread. Researchers want to see if this dietary approach helps the treatment work better and reduces side effects.
Hear when a new Non-Small Cell Lung Cancer With EGFR Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.